Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
6.63 USD +1.69% Intraday chart for AxoGen, Inc. +2.00% -2.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing MT
AxoGen, Inc. Announces Executive Changes CI
AxoGen Files $100 Million Mixed-Securities Shelf MT
Health Care Down After Mixed Earnings -- Health Care Roundup DJ
Transcript : AxoGen, Inc., Q4 2023 Earnings Call, Mar 05, 2024
AxoGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
AxoGen Says Trial of Axoguard Nerve Cap Met Primary Endpoint of Pain Reduction MT
Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study CI
Axogen Expects Higher Q4 Revenue; CEO Plans to Retire MT
AxoGen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 CI
AxoGen, Inc. Revises Revenue Guidance for the Full Year of 2023 CI
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 CI
Axogen, Inc. Announces Plans to Retirement of Karen Zaderej as President, Effective January 2025 CI
AxoGen, Inc. Announces Executive Changes CI
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors CI
AxoGen, Inc. Announces CFO Changes CI
AxoGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : AxoGen, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (AXGN) AXOGEN Posts Q3 Revenue $41.3M, vs. Street Est of $40.3M MT
Earnings Flash (AXGN) AXOGEN Posts Q3 EPS $0.01, vs. Street Est of $-0.06 MT
AXOGEN INC - CONTINUES TO EXPECT GROSS MARGIN FOR FULL YEAR 2023… RE
Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023 CI
AxoGen, Inc.(NasdaqCM:AXGN) dropped from S&P Healthcare Equipment Select Industry Index CI
Chart AxoGen, Inc.
More charts
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.63 USD
Average target price
13.8 USD
Spread / Average Target
+108.14%
Consensus
  1. Stock Market
  2. Equities
  3. AXGN Stock
  4. News AxoGen, Inc.
  5. AxoGen Files $100 Million Mixed-Securities Shelf